Overview

A Study Assessing the Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.

Phase:

Phase 2

Details

Lead Sponsor:

Suzhou Connect Biopharmaceuticals, Ltd.